Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin

References

• Cahn A Cefalu WT Clinical considerations for use of initial combination therapy in type 2 diabetes Diabetes Care 2016 39 suppl 2 S137 S145 27440826
   PubMed Web of Science ®Google Scholar
• Hayward RA Reaven PD Wiitala WL Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes N Engl J Med 2015 372 23 2197 2206 26039600
   PubMed Web of Science ®Google Scholar
• Gerstein HC Miller ME Ismail-Beigi F ACCORD Study Group Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial Lancet 2014 384 9958 1936 1941 25088437
   PubMed Web of Science ®Google Scholar
• ADVANCE Collaborative Group Patel A MacMahon S Chalmers J Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 2008 2008 358 2560 2572
   Google Scholar
• Ismail-Beigi F Craven T Banerji MA ACCORD Trial Group Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial Lancet 2010 376 9739 419 430 20594588
   PubMed Web of Science ®Google Scholar
• Inzucchi S Bergenstal R Buse JB Management of hyperglycemia in type 2 diabetes: a patient-centered approach – position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2012 35 1364 1379 2013 36 2 490 22517736
   PubMed Web of Science ®Google Scholar
• Inkster B Zammitt NN Frier BM Drug-induced hypoglycaemia in type 2 diabetes Expert Opin Drug Saf 2012 11 4 597 614 22690846
   PubMed Web of Science ®Google Scholar
• Nesto RW Bell D Bonow RO Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association Diabetes Care 2004 27 1 256 263 14693998
   PubMed Web of Science ®Google Scholar
• Goring S Hawkins N Wygant G Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin mono-therapy: a systematic review and network meta-analysis Diabetes Obes Metab 2014 16 5 433 442 24237939
   PubMed Web of Science ®Google Scholar
• Florez H Luo J Castillo-Florez S Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes Postgrad Med 2010 122 2 112 120
   PubMed Web of Science ®Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study Group Gerstein HC Miller ME Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 2008 358 24 2545 2559 18539917
   PubMed Web of Science ®Google Scholar
• Canadian Diabetes Association Clinical Practice Guidelines Expert Committee Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada Can J Diabetes 2013 37 suppl 1 S1 S212 24070926
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach – update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2015 38 1 140 149 25538310
   PubMed Web of Science ®Google Scholar
• Garber AJ Abrahamson MJ Barzilay JI AACE/ACE Comprehensive Diabetes Management Algorithm 2015 Endocr Prac 2015 21 4 438 447
   PubMed Web of Science ®Google Scholar
• List JF Woo V Morales E Tang W Fiedorek FT Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes Diabetes Care 2009 32 4 650 657 19114612
   PubMed Web of Science ®Google Scholar
• Merovci A Solis-Herrera C Daniele G Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production J Clin Invest 2014 124 2 509 514 24463448
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani M Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes? Diabetes Care 2015 38 3 373 375 25715413
   PubMed Web of Science ®Google Scholar
• European Medicines Agency Qtern: EPAR product information 2016
   Google Scholar
• Thom S Poulter N Field J UMPIRE Collaborative Group Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: The UMPIRE randomized clinical trial JAMA 2013 310 9 918 929 24002278
   PubMed Web of Science ®Google Scholar
• Thayer S Arondekar B Harley C Darkow TE Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea Ann Pharmacother 2010 44 5 791 799 20371759
   PubMed Web of Science ®Google Scholar
• Singh-Franco D Potential for dipeptidyl peptidase-4 inhibitor and sodium glucose cotransporter 2 inhibitor single-pill combinations Expert Rev Endocrinol Metab 2015 10 3 305 317
   PubMed Web of Science ®Google Scholar
• European Medicines Agency Qtern: Summary of Product Characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004057/WC500211093.pdf Accessed January 25, 2017
   Google Scholar
• U.S. Food and Drug Administration QTERN Full Prescribing Information Available from: https://www.accessdata.fda.gov/drug-satfda_docs/label/2017/209091s000lbl.pdf Accessed March 17, 2017
   Google Scholar
• Thornberry NA Gallwitz B Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4) Best Pract Res Clin Endocrinol Metab 2009 23 4 479 486 19748065
   PubMed Web of Science ®Google Scholar
• Verspohl EJ Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors Pharmacol Ther 2009 124 1 113 138 19545590
   PubMed Web of Science ®Google Scholar
• Drucker DJ Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2006 368 9548 1696 1705 17098089
   PubMed Web of Science ®Google Scholar
• Ahrén B Foley JE Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism Diabetologia 2016 59 5 907 917 26894277
   PubMed Web of Science ®Google Scholar
• Ahrén B Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin–diabetes control and potential adverse events Best Pract Res Clin Endocrinol Metab 2009 23 4 487 498 19748066
   PubMed Web of Science ®Google Scholar
• Schernthaner G Gross JL Rosenstock J Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial Diabetes Care 2013 36 9 2508 2515 23564919
   PubMed Web of Science ®Google Scholar
• Boulton DW Clinical pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor Clin Pharmacokinet 2016 56 1 1 14
   Web of Science ®Google Scholar
• Rosenstock J Sankoh S List J Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes Diabetes Obes Metab 2008 10 5 376 386 18355324
   PubMed Web of Science ®Google Scholar
• Endocrinologic and Metabolic Drugs Advisory Committee Briefing Material on NDA 22350: Saxagliptin and NDA 200678: Saxagliptin/Metformin Food and Drug Administration (FDA) 2015 Available from: https://www.fda.gov/downloads/advisorycommittees/commit-teesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvi-sorycommittee/ucm442060.pdf Accessed December 15, 2016
   Google Scholar
• Scheen A Pharmacokinetics of dipeptidylpeptidase-4 inhibitors Diabetes Obes Metab 2010 12 8 648 658 20590741
   PubMed Web of Science ®Google Scholar
• Deacon CF Holst JJ Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety Expert Opin Pharmacother 2013 14 15 2047 2058 23919507
   PubMed Web of Science ®Google Scholar
• Frederich R McNeill R Berglind N Fleming D Chen R The effi-cacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial Diabetol Metab Syndr 2012 4 1 36 47 22828124
   PubMed Web of Science ®Google Scholar
• Rosenstock J Aguilar-Salinas C Klein E Nepal S List J Chen R Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes Curr Med Res Opin 2009 25 10 2401 2411 19650754
   PubMed Web of Science ®Google Scholar
• Jadzinsky M Pfützner A Paz-Pacheco E CV181-039 Investigators Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial Diabetes Obes Metab 2009 11 6 611 622 19515181
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Hissa MN Garber AJ Saxagliptin 014 Study Group The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone Diabetes Care 2009 32 9 1649 1655 19478198
   PubMed Web of Science ®Google Scholar
• Gu W Liang L Wang S SUNSHINE Study Group Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24-week, post-marketing SUNSHINE study J Diabetes 2016 8 6 809 815 26676908
   PubMed Web of Science ®Google Scholar
• Hermans MP Delibasi T Farmer I Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: The PROMPT study Curr Med Res Opin 2012 28 10 1635 1645 23020253
   PubMed Web of Science ®Google Scholar
• Li C Liu X Bai L Efficacy and safety of vildagliptin, saxagliptin or sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents Diabetol Metab Syndr 2014 6 1 69 24917890
   PubMed Web of Science ®Google Scholar
• Chacra AR Tan GH Ravichandran S List J Chen R CV181040 Investigators Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks Diab Vasc Dis Res 2011 8 2 150 159 21562067
   PubMed Web of Science ®Google Scholar
• Chacra AR Tan G Apanovitch A CV181-040 Investigators Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial Int J Clin Pract 2009 63 9 1395 1406 19614786
   PubMed Web of Science ®Google Scholar
• Hollander P Li J Allen E Chen R Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone J Clin Endocrinol Metabol 2009 94 12 4810 4819
   PubMed Web of Science ®Google Scholar
• Hollander PL Li J Frederich R Allen E Chen R CV181013 Investigators Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus Diab Vasc Dis Res 2011 8 2 125 135 21562064
   PubMed Web of Science ®Google Scholar
• Barnett AH Charbonnel B Donovan M Fleming D Chen R Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin Curr Med Res Opin 2012 28 4 513 523 22313154
   PubMed Web of Science ®Google Scholar
• Li FF Jiang LL Yan RN Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: a randomized, control, open-labeled trial Medicine (Baltimore) 2016 95 43 e5229 27787387
   PubMed Web of Science ®Google Scholar
• Defronzo RA Banting lecture from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 2009 58 4 773 795 19336687
   PubMed Web of Science ®Google Scholar
• Göke B Gallwitz B Eriksson J Hellqvist Å Gause-Nilsson I D1680C00001 Investigators Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial Int J Clin Pract 2010 64 12 1619 1631 20846286
   PubMed Web of Science ®Google Scholar
• Göke B Gallwitz B Eriksson JG Hellqvist Å Gause-Nilsson I Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial Int J Clin Pract 2013 67 4 307 316 23638466
   PubMed Web of Science ®Google Scholar
• Hirshberg B Parker A Edelberg H Donovan M Iqbal N Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus Diabetes Metab Res Rev 2014 30 7 556 569 24376173
   PubMed Web of Science ®Google Scholar
• Neumiller JJ Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetes Clin Diabetes 2014 32 4 170 177 25646943
   PubMedGoogle Scholar
• Cernea S Cahn A Raz I Saxagliptin for the treatment of diabetes – a focus on safety Expert Opin Drug Saf 2016 15 5 697 707 26923222
   PubMed Web of Science ®Google Scholar
• Scirica BM Bhatt DL Braunwald E Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 2013 369 14 1317 1326 23992601
   PubMed Web of Science ®Google Scholar
• Scirica BM Braunwald E Raz I SAVOR-TIMI 53 Steering Committee and Investigators Heart failure, saxagliptin, and diabetes mellitus: Observations from the SAVOR-TIMI 53 randomized trial Circulation 2014 130 18 1579 1588 25189213
   PubMed Web of Science ®Google Scholar
• Monami M Dicembrini I Mannucci E Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials Diabetes Obes Metab 2014 16 1 48 56 23837679
   PubMed Web of Science ®Google Scholar
• Karyekar CS Ravichandran S Allen E Fleming D Frederich R Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥65 years) with inadequately controlled type 2 diabetes mellitus Clin Interv Aging 2013 8 419 430 23626461
   PubMed Web of Science ®Google Scholar
• Leiter LA Teoh H Braunwald E SAVOR-TIMI 53 Steering Committee and Investigators Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial Diabetes Care 2015 38 6 1145 1153 25758769
   PubMed Web of Science ®Google Scholar
• Meng W Ellsworth BA Nirschl AA Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes J Med Chem 2008 51 5 1145 1149 18260618
   PubMed Web of Science ®Google Scholar
• Chao EC Henry RR SGLT2 inhibition – a novel strategy for diabetes treatment Nat Rev Drug Discov 2010 9 7 551 559 20508640
   PubMed Web of Science ®Google Scholar
• Han S Hagan DL Taylor JR Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats Diabetes 2008 57 6 1723 1729 18356408
   PubMed Web of Science ®Google Scholar
• Rahmoune H Thompson PW Ward JM Smith CD Hong G Brown J Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes Diabetes 2005 54 12 3427 3434 16306358
   PubMed Web of Science ®Google Scholar
• Komoroski B Vachharajani N Boulton D Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects Clin Pharmacol Ther 2009 85 5 520 526 19129748
   PubMed Web of Science ®Google Scholar
• Komoroski B Vachharajani N Feng Y Li L Kornhauser D Pfister M Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus Clin Pharmacol Ther 2009 85 5 513 519 19129749
   PubMed Web of Science ®Google Scholar
• Ferrannini E Ramos SJ Salsali A Tang W List JF Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial Diabetes Care 2010 33 10 2217 2224 20566676
   PubMed Web of Science ®Google Scholar
• Ji L Ma J Li H Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study Clin Ther 2014 36 1 84.e9 100.e9 24378206
   PubMed Web of Science ®Google Scholar
• Kalra S Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology Diabetes Ther 2014 5 2 355 366 25424969
   PubMed Web of Science ®Google Scholar
• Anderson SL Dapagliflozin efficacy and safety: a perspective review Ther Adv Drug Saf 2014 5 6 242 254 25436106
   PubMedGoogle Scholar
• Bailey C Iqbal N T’joen C List J Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range Diabetes Obes Metab 2012 14 10 951 959 22776824
   PubMed Web of Science ®Google Scholar
• FDA Drug Label Farxiga (dapagliflozin) 2014 No. Reference ID: 3606617
   Google Scholar
• Bailey C Morales Villegas E Woo V Tang W Ptaszynska A List J Efficacy and safety of dapagliflozin monotherapy in people with type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial Diabet Med 2015 32 4 531 541 25381876
   PubMed Web of Science ®Google Scholar
• Bolinder J Ljunggren Ö Johansson L Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin Diabetes Obes Metab 2014 16 2 159 169 23906445
   PubMed Web of Science ®Google Scholar
• Bolinder J Ljunggren Ö Kullberg J Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin J Clin Endocrinol Metab 2011 97 3 1020 1031
   Web of Science ®Google Scholar
• Strojek K Yoon K Hruba V Sugg J Langkilde AM Parikh S Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial Diabetes Ther 2014 5 1 267 283 24920277
   PubMed Web of Science ®Google Scholar
• Strojek K Yoon K Hruba V Elze M Langkilde A Parikh S Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial Diabetes Obes Metab 2011 13 10 928 938 21672123
   PubMed Web of Science ®Google Scholar
• Bailey CJ Gross JL Pieters A Bastien A List JF Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial Lancet 2010 375 9733 2223 2233 20609968
   PubMed Web of Science ®Google Scholar
• Del Prato S Nauck M Durán-Garcia S Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data Diabetes Obes Metab 2015 17 6 581 590 25735400
   PubMed Web of Science ®Google Scholar
• Nauck M Del Prato S Durán-García S Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin Diabetes Obes Metab 2014 16 11 1111 1120 24919526
   PubMed Web of Science ®Google Scholar
• Rosenstock J Vico M Wei L Salsali A List JF Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy Diabetes Care 2012 35 7 1473 1478 22446170
   PubMed Web of Science ®Google Scholar
• Jabbour SA Hardy E Sugg J Parikh S Study 10 Group Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study Diabetes Care 2014 37 3 740 750 24144654
   PubMed Web of Science ®Google Scholar
• Kaku K Maegawa H Tanizawa Y Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study Diabetes Ther 2014 5 2 415 433 25341477
   PubMed Web of Science ®Google Scholar
• Wilding JP Woo V Soler NG Dapagliflozin 006 Study Group Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial Ann Intern Med 2012 156 6 405 415 22431673
   PubMed Web of Science ®Google Scholar
• Wilding JP Norwood P T’joen C Bastien A List JF Fiedorek FT A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment Diabetes Care 2009 32 9 1656 1662 19528367
   PubMed Web of Science ®Google Scholar
• Wilding J Woo V Rohwedder K Sugg J Parikh S Dapagliflozin 006 Study Group Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years Diabetes Obes Metab 2014 16 2 124 136 23911013
   PubMed Web of Science ®Google Scholar
• Ptaszynska A Johnsson KM Parikh SJ De Bruin TW Apanovitch AM List JF Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events Drug Safety 2014 37 10 815 829 25096959
   PubMed Web of Science ®Google Scholar
• Heerspink H Johnsson E Gause-Nilsson I Cain V Sjöström C Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving rennin-angiotensin blockers Diabetes Obes Metab 2016 18 6 590 597 26936519
   PubMed Web of Science ®Google Scholar
• Barnett AH Mithal A Manassie J EMPA-REG RENAL Trial Investigators Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial Lancet Diabetes Endocrinol 2014 2 5 369 384 24795251
   PubMed Web of Science ®Google Scholar
• Johnsson KM Ptaszynska A Schmitz B Sugg J Parikh SJ List JF Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin J Diabetes Complications 2013 27 5 479 484 23806570
   PubMed Web of Science ®Google Scholar
• Johnsson KM Ptaszynska A Schmitz B Sugg J Parikh SJ List JF Urinary tract infections in patients with diabetes treated with dapagliflozin J Diabetes Complications 2013 27 5 473 478 23849632
   PubMed Web of Science ®Google Scholar
• Briand F Mayoux E Brousseau E Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism Diabetes 2016 65 7 2032 2038 27207551
   PubMed Web of Science ®Google Scholar
• Ferrannini E Muscelli E Frascerra S Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients J Clin Invest 2014 124 2 499 508 24463454
   PubMed Web of Science ®Google Scholar
• Daniele G Xiong J Solis-Herrera C Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes Diabetes Care 2016 39 11 2036 2041 27561923
   PubMed Web of Science ®Google Scholar
• Sonesson C Johansson PA Johnsson E Gause-Nilsson I Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis Cardiovasc Diabetol 2016 15 1 37 26895767
   PubMed Web of Science ®Google Scholar
• Wu JH Foote C Blomster J Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis Lancet Diabetes Endocrinol 2016 4 5 411 419 27009625
   PubMed Web of Science ®Google Scholar
• Sattar N McLaren J Kristensen SL Preiss D McMurray JJ SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia 2016 59 7 1333 1339 27112340
   PubMed Web of Science ®Google Scholar
• Hayashi T Fukui T Nakanishi N Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin Cardiovasc Diabetol 2017 16 1 8 28086872
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration [webpage on the Internet]. FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections 2016 [updated 2016]. Drug Safety Communications Web site. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm Accessed January 27, 2017
   Google Scholar
• Handelsman Y Henry RR Bloomgarden ZT American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis Endocr Prac 2016 22 6 753 762
   PubMed Web of Science ®Google Scholar
• Rosenstock J Hansen L Zee P Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin Diabetes Care 2015 38 3 376 25352655
   PubMed Web of Science ®Google Scholar
• Matthaei S Catrinoiu D Celinski A Randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes Diabetes Care 2015 38 11 2018 2024 26324329
   PubMed Web of Science ®Google Scholar
• Matthaei S Aggarwal N Garcia-Hernandez P One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin Diabetes Obes Metab 2016 18 11 1128 1133 27403645
   PubMed Web of Science ®Google Scholar
• Mathieu C Ranetti AE Li D Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes Diabetes Care 2015 38 11 2009 2017 26246458
   PubMed Web of Science ®Google Scholar
• Mathieu C Herrera Marmolejo M González González J Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes Diabetes Obes Metab 2016 18 11 1134 1137 27385192
   PubMed Web of Science ®Google Scholar
• Bell D Combine and conquer: advantages and disadvantages of fixed-dose combination therapy Diabetes Obes Metab 2013 15 4 291 300 23013323
   PubMed Web of Science ®Google Scholar
• Woo V Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option Int J Clin Pract 2015 69 12 1427 1437 26303997
   PubMed Web of Science ®Google Scholar